WO2015011722A2 - Zolpidem, method of preparation and an intermediate therein - Google Patents

Zolpidem, method of preparation and an intermediate therein Download PDF

Info

Publication number
WO2015011722A2
WO2015011722A2 PCT/IN2014/000481 IN2014000481W WO2015011722A2 WO 2015011722 A2 WO2015011722 A2 WO 2015011722A2 IN 2014000481 W IN2014000481 W IN 2014000481W WO 2015011722 A2 WO2015011722 A2 WO 2015011722A2
Authority
WO
WIPO (PCT)
Prior art keywords
formula
compound
group
zolpidem
solvent
Prior art date
Application number
PCT/IN2014/000481
Other languages
English (en)
French (fr)
Other versions
WO2015011722A3 (en
Inventor
Alok Ardaman SINGH
Atulkumar Deonath DHALE
Original Assignee
3A Chemie Private Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 3A Chemie Private Limited filed Critical 3A Chemie Private Limited
Publication of WO2015011722A2 publication Critical patent/WO2015011722A2/en
Publication of WO2015011722A3 publication Critical patent/WO2015011722A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Definitions

  • the present disclosure relates to a method of preparation of Zolpidem, particularly to a method of preparation of Zolpidem using a novel intermediate.
  • Zolpidem an imidazo pyridine represented by Formula 6, is one of the most commonly prescribed hypnotics for the treatment of insomnia and other brain disorders such as convulsions and anxiety.
  • Zolpidem has a short half-life and is a non-benzodiazepine, fast-acting hypnotic that binds selectively to the GABA A receptor subtypes, the usual onset of action being within 15 minutes of administration.
  • 6-Methyl-2-(4-methylphenyl)imidazo[l,2-a]pyridine a compound represented by Formula 1, is the basic starting material for the preparation of Zolpidem.
  • the Tschitschibabin reaction represented by Scheme 1, is a method conventionally followed for the preparation of the compound of Formula 1.
  • toluene is reacted with chloroacetylchloride under Friedel-Crafts acylation conditions followed by condensation with 2-amino-5- methylpyridine to provide the compound of Formula 1.
  • EP0050563 suggests a process for the preparation of Zolpidem as schematically represented in Scheme 2.
  • EP0050563 uses low boiling, highly expensive and toxic reagents such as methyl iodide that makes the process cost-inefficient and non-amenable to large scale.
  • US 4492695 avoids the use of expensive and toxic reagent i.e., methyl iodide; however it involves a relatively more number of steps. Further, the reaction time of some of the steps of US4492695 is relatively long, thereby making the process energy inefficient. Still further, the yield of Zolpidem is relatively low and the workup procedure to isolate Zolpidem is complex.
  • WO2009007995 suggests a process represented in Scheme 4 for the preparation of Zol idem.
  • WO2009007995 uses alkyl chloroformates which are as toxic as methyl iodide. Further, the alkyl chloroformates are difficult to handle due to their low vapor pressure and lachrymatic properties. Even further, the process suffers from tedious work-up method which is undesirable for commercial production.
  • the inventors of the present disclosure thus, provide a process for the preparation of Zolpidem that can be readily scaled up, does not require special purification steps and which employs inexpensive, readily available, easy to handle and non-toxic reagents.
  • an intermediate for the preparation of Zolpidem said intermediate having a structure of Formula 3, wherein R is selected from the group comprising ethyl, methyl, propyl, butyl, isopropyl, isobutyl and tertiary butyl group.
  • a process for the preparation of an intermediate of Formula 3 by alkylating a compound of Formula 2 comprising the following steps: first, a solution comprising Formula 2 and a first solvent is prepared; then a compound of Formula 7 is added to the prepared solution at a temperature ranging from -5 °C to 15 °C to obtain a reaction mixture; the reaction mixture is refluxed at a temperature ranging from 35 °C to the boiling point of the first solvent to obtain a compound of Formula 3.
  • the compound of Formula 4 is hydrolyzed said using an aqueous solution of at least one base and at least one second solvent to obtain a compound of Formula 5;
  • Zolpidem an imidazo pyridine is one of the most commonly prescribed hypnotics for the treatment of insomnia and other brain disorders such as convulsions and anxiety.
  • Zolpidem has a short half-life and is a non-benzodiazepine, fast-acting hypnotic that binds selectively to the GABA A receptor subtypes, the usual onset of action being within 15 minutes of administration.
  • the basic starting material for preparation of Zolpidem is 6-Methyl-2- (4-methylphenyl)imidazo[l,2-a]pyridine (compound of Formula 1).
  • compounds of Formula 1 6-Methyl-2- (4-methylphenyl)imidazo[l,2-a]pyridine.
  • the present disclosure therefore, provides a process for preparation of Zolpidem that can be easily scaled up, does not require additional purification steps and employs inexpensive, readily available, easy to handle and non-toxic reagents.
  • the present disclosure provides a novel intermediate having a structure of compound of formula 3, for the preparation of Zolpidem and a process for preparing the novel intermediate.
  • a compound of Formula 7 i.e., dialkyl sulfate is added at a temperature ranging from -5 °C to 15 °C to the solution of compound of Formula 2 i.e., (2-(4-methylphenyl)-6-methyl-3-dimethylaminomethyl imidazo [l,2-a]pyridine) and solvent/s to obtain a reaction mixture.
  • the reaction mixture is then heated to a boiling point of the solvent being used in the first step to obtain a compound of Formula 3 (a quaternary ammonium salt of Mannich base of the compound of Formula 2) after heating the reaction mixture for a time period of 15 to 480 minutes.
  • the R group in the compound of Formula 7 is selected from a group comprising ethyl, methyl, propyl butyl, isopropyl, isobutyl and tertiary butyl group.
  • the molar ratio of the compound of Formula 2 to the compound of Formula 7 is optimized in the range of 1:0.5 to 1:3.
  • the optimized molar ratio of the compound of Formula 2 to the compound of Formula 7 ranges from 1:1 to 1:1.5.
  • Solvents that can be used in the present disclosure include halogenated solvent, alcohol solvent and ketone solvent.
  • Non-limiting examples of the solvent include dichloromethane, dichloroethane, chloroform, acetone, methanol, ethanol, ethyl acetate and the like.
  • Non-limiting examples of the dialkyl sulfate represented by Formula 7 include diethyl sulfate, dipropyl sulfate, dibutyl sulfate, di-isopropyl sulfate, di-isobutyl sulfate, dimethyl sulfate and the like.
  • dialkyl sulfate is dimethyl sulfate.
  • the compound of Formula 3 prepared in accordance with the process of the present disclosure is subjected to cyanation reaction using an aqueous solution of sodium cyanide to obtain a nitrile derivative represented by Formula 4 (6-methyl-2-(4- methylphenyl)imidazo[l,2-a]pyridine-3-acetonitrile).
  • the cyanation reaction is carried out at a temperature ranging from 10 °C to 100 °C for a time period of 1 to 6 hours.
  • the compound of Formula 3 is isolated from the solvent prior to cyanation with sodium cyanide.
  • the compound of Formula 3 is reacted as such, in-situ, for cyanation with sodium cyanide.
  • the compound of Formula 3 is dissolved in water and the pH is adjusted in the range of 6.0 to 10.0 using a pH adjusting agent before subjecting it to the cyanation reaction.
  • Non-limiting examples of pH adjusting agent include potassium carbonate, sodium bicarbonate, sodium hydride and sodium hydroxide.
  • the compound of Formula 4 prepared in accordance with the present disclosure is further hydrolyzed using an aqueous solution of a base and at least one solvent to obtain an acid represented by the Formula 5 (6-methyl-2-(4- methylphenyl)imidazo[l,2-a]pyridine-3- acetic acid).
  • Non-limiting examples of the base include potassium hydroxide, sodium hydroxide, barium hydroxide, sodium carbonate and ammonia.
  • Non-limiting examples of the solvent include methanol, ethanol and acetone.
  • the compound of Formula 5 prepared in accordance with the present disclosing is initially reacted with an acyl halide forming agent to obtain an acyl halide derivative represented by formula 8.
  • the compound of Formula 8 is moisture sensitive and therefore not isolated, though it can be, and is further reacted with dimethyl amine to obtain Zolpidem having the structure of Formula 6 (6-methyl-2-(4- methylphenyl)imidazo[l,2-a]pyridine-3-N,N-dimethylacetamide).
  • the acyl halide forming agent in accordance with the present disclosure is phosphorus oxychloride, phosphorus penta chloride, phosphorus trichloride, thionyl chloride and combinations thereof.
  • the process of the present disclosure prepares the compound of Formula 5 (6-methyl- 2-(4-methylphenyl)imidazo[l,2-a]pyridine-3-acetic acid) without isolation and purification of intermediate products thereby saving the time and increasing the productivity.
  • the overall progression of the reaction for the preparation of Zolpidem in accordance with the present disclosure is represented in Scheme 5.
  • reaction mass was cooled to 10 °C, the product was filtered and taken in a reactor containing 1200 ml of 6.25%sodium cyanide solution.
  • the resultant reaction mass was heated and then maintained at 85 °C for 4 hours and then cooled to about 25 °C, filtered and washed thoroughly with water to remove excess sodium cyanide.
  • the filtered compound was dried at 100 °C to yield 133 g of title compound, 6-methyl-2-(4- methylphenyl)imidazo[l,2-a]pyridine-3-acetonitrile.
  • HPLC High Performance Liquid Chromatography
  • the reaction mass was then heated slowly to 80-85 °C and maintained for 2 hours to distill out methanol.
  • the reaction mass was cooled to about 25 °C, filtered and washed thoroughly with water to remove excess sodium cyanide.
  • the filtered compound was dried at 100 °C to yield 95 g of the compound of Formula 4. HPLC purity of the compound was found to be 87%.
  • the compound prepared in Example 1 was taken into a reactor containing 600 ml of methanol and 600 ml of water along with 100 g of potassium hydroxide.
  • the reaction mixture was refluxed for 15 hours till the completion of the reaction and was followed by distillation with methanol (600-700 ml of methanol-water).
  • the aqueous reaction mass was cooled to about 25 °C and washed thrice with methylene chloride.
  • the aqueous layer was then acidified with acetic acid to precipitate the product.
  • the white solid material obtained was filtered and washed with water.
  • 121 g (0.432 mol) of 6- methyl-2-(4-methylphenyl)imidazo[l,2-a]pyridine-3- acetic acid was the yield obtained having 99.70%HPLC purity.
  • reaction mass was then cooled to 10 °C and dimethylamine gas was purged into the reaction mass at 10-15 °C, till the pH ranged between 9 and 10.
  • the reaction mass was further heated to 50 °C and maintained for 1 hour.
  • the reaction mass was cooled to 25 °C and a solution of sodium bicarbonate (12 g in 240 ml water) was added to the reaction mass.
  • the reaction mass was maintained at 25-30 °C for 2 hours and further cooled to 5-10 °C and maintained at this temperature for 4 hours.
  • the reaction mass was filtered and washed with 1 liter of hot water and further with 100 ml of chilled ethyl acetate.
  • the filtered material was dried under vacuum at 75 °C until constant weight was reached. Dry weight of the resultant compound (Zolpidem) was found to be 120.0 grams.
  • the process of present disclosure also provides a process for the preparation of Zolpidem in less number of steps which reduces time and increases the productivity.
  • the process of present disclosure provides a process for preparation of Zolpidem using inexpensive, readily available and non-toxic reagents.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PCT/IN2014/000481 2013-07-22 2014-07-22 Zolpidem, method of preparation and an intermediate therein WO2015011722A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2428/MUM/2013 2013-07-22
IN2428MU2013 IN2013MU02428A (enrdf_load_stackoverflow) 2013-07-22 2014-07-22

Publications (2)

Publication Number Publication Date
WO2015011722A2 true WO2015011722A2 (en) 2015-01-29
WO2015011722A3 WO2015011722A3 (en) 2015-03-26

Family

ID=52393906

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2014/000481 WO2015011722A2 (en) 2013-07-22 2014-07-22 Zolpidem, method of preparation and an intermediate therein

Country Status (2)

Country Link
IN (1) IN2013MU02428A (enrdf_load_stackoverflow)
WO (1) WO2015011722A2 (enrdf_load_stackoverflow)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107383005A (zh) * 2017-09-11 2017-11-24 华东理工大学 6‑甲基‑2‑(4‑甲基苯基)咪唑并[1,2‑a]吡啶‑3‑乙酸的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1076089A (en) * 1965-11-09 1967-07-19 Selvi & C Lab Bioterapico New derivatives of imidazo [1,2-a]-pyridine and a process for the manufacture thereof
FR2492382A1 (fr) * 1980-10-22 1982-04-23 Synthelabo Derives d'imidazo (1,2-a) pyridine, leur preparation et leur application en therapeutique
AU8086001A (en) * 2000-08-07 2002-02-18 Procter & Gamble Company, The Sulfation process

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107383005A (zh) * 2017-09-11 2017-11-24 华东理工大学 6‑甲基‑2‑(4‑甲基苯基)咪唑并[1,2‑a]吡啶‑3‑乙酸的制备方法

Also Published As

Publication number Publication date
IN2013MU02428A (enrdf_load_stackoverflow) 2015-06-19
WO2015011722A3 (en) 2015-03-26

Similar Documents

Publication Publication Date Title
TWI744723B (zh) 多環型胺甲醯基吡啶酮化合物之合成
KR101008364B1 (ko) 라세믹 옥시라세탐, (ｓ)-옥시라세탐, 또는 그 유도체의 제조방법
JP6811717B2 (ja) トピロキソスタット及びその中間体の調製のための方法
WO2010055042A1 (en) 2-[(1-cyanopropyl)carbamoyl]-5-methoxymethyl nicotinic acids and the use thereof in manufacturing herbicidal imidazolinones
US20140128600A1 (en) Methods for preparing naphthyridines
US10815216B2 (en) Process for the preparation of aripiprazole lauroxil
WO2015011722A2 (en) Zolpidem, method of preparation and an intermediate therein
US9278939B2 (en) Methods for preparation of (4,6-dihalo-pyrimidin-5-yl)-acetaldehydes
WO2020201974A1 (en) Novel process for preparation of key intermediate of pinoxaden
CA2767946A1 (en) Process for preparing levosimendan and intermediates for use in the process
US9695204B2 (en) Pharmaceutical process and intermediates
CN106432233B (zh) N,N,6-三甲基-2-(4-甲基苯基)咪唑并[1,2-a]吡啶-3-乙酰胺的制备方法
TW201920076A (zh) 製備經取代４－胺基二氫茚衍生物之方法
EP2928892B1 (en) An improved process for the preparation of moxifloxacin hydrochloride
US20130085278A1 (en) Methods for the preparation of 5-[2-[7 (trifluoromethyl)-5-[4- (trifluoromethyl)phenyl]pyrazolo [1,5-a]pyrimidin-3-yl]ethynyl]-2-pyridinamine
JP2010037206A (ja) 光学活性なｏ−メチルセリンまたはその塩の製造法
JPH0662577B2 (ja) １−メチル−５−ヒドロキシピラゾ−ルの製造法
US9611217B2 (en) Synthetic processes of carprofen
TWI361807B (en) Process for preparing substituted 4-alkoxycarbonyl-3-aminothiophenes
JP2515326B2 (ja) テトラヒドロ−２（１ｈ）−ピリミジノン類の製造方法
US8076479B2 (en) Process and intermediates for the synthesis of (3-alkyl-5-piperidin-1-yl-3,3a-dihydro-pyrazolo[1,5-a]pyrimidin-7-yl)-amino derivatives and intermediates
TWI453182B (zh) Ｒ－β－胺基苯丁酸衍生物的製備方法
WO2009103787A1 (en) Process for the preparation of 2,3,4,9-tetrahydro-1h-beta-carbolin-3-carboxylic acid esters"
DK153472B (da) Fremgangsmaade til fremstilling af alfa-anilinocarboxylsyrenitriler
JPH07291933A (ja) ２，５−二置換ピリジン類の製造方法

Legal Events

Date Code Title Description
NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14829360

Country of ref document: EP

Kind code of ref document: A2